APOE ε4 increases the risk for developing AD dose-dependently and also decreases the age of disease onset (Corder et al., 1993; Roses, 1994; Frisoni et al., 1995; Farrer et al., 1997). The gene discussed is APOE; the disease is Alzheimer disease.